Cancer cachexia is a wasting syndrome, which is characterized by weight loss, anorexia (loss of desire to eat), asthenia and anemia. The pathogenicity of this syndrome is multifactorial, due to a complex interaction of tumor and host factors. It occurs in patients with advanced cancer, chronic obstructive pulmonary disease, chronic infection including AIDS and tuberculosis, chronic heart failure, and rheumatoid arthritis. However, the occurrence of cancer cachexia is high, especially in patients with advanced cancer, this syndrome often remains underdiagnosed.
Multiple abnormalities in protein, fat, and carbohydrate metabolism as well as peripheral hormone and neuropeptide metabolism have been reported as the cause of cancer cachexia. Investigations in humans suggest a central role of tumor‐induced inflammation as the primary cause of cachexia development.
Get FREE sample copy at:
https://www.delveinsight.com/sample-request/Cancer-cachexia-CC-market-insights%20
The Cancer Cachexia market report also covers emerging drugs, current treatment practices, Cancer Cachexia market share of the individual therapies, current and forecasted Cancer Cachexia Market Size from 2017 to 2030 segmented by seven major markets.
The report provides a detailed current Cancer Cachexia treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Cancer Cachexia Market Key Facts
As per a Japanese study conducted by Aoyagi et al. “Cancer cachexia, mechanism and treatment”, cachexia occurs in the majority of terminal cancer patients and is responsible for the death of 22% of cancer patients.
Several secondary studies suggest that the overall incidence of cachexia is high and in industrialized countries, such as, North America, Europe, Japan it is growing. It is currently estimated that cachexia affects approximately 9 million patients, which is about 1% of all patients with any disease.
It is estimated that more than 30% of cancer patients die due to cachexia, and more than 50% of patients die with cachexia being present.
Key Benefits of Cancer Cachexia Market Report
-
Cancer Cachexia market report provides an in-depth analysis of Cancer Cachexia Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major market i.e. EU5 (Germany, Italy, Spain, France and the UK), Japan, and the United States.
-
The Cancer Cachexia market report will help in developing business strategies by understanding the Cancer Cachexia Market trends & developments, key players and future market competition that will shape and drive the Cancer Cachexia market in the upcoming years.
-
The Cancer Cachexia market report covers Cancer Cachexia current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
-
The report provides a detailed assessment of the Cancer Cachexia market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population, comparative analysis of pipeline products with detailed clinical profiles, and other factors.
The Cancer Cachexia market outlook section of the report helps to build the detailed comprehension of the historic, current and forecasted Cancer Cachexia market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology.
The report gives a thorough detail of Cancer Cachexia market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Cancer Cachexia Epidemiology
The Cancer Cachexia epidemiology section covers insights about historical and current Cancer Cachexia patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
According to the Cancer Cachexia Hub, approximately half of all patients with cancer experience cachexia. This rate of occurrence rises to as high as 86% in the last 1–2 weeks of life, and with 45% of patients losing more than 10% of their original body weight over disease progression.
Cancer Cachexia Drugs Uptake and Key Market Players
The Cancer Cachexia Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Cancer Cachexia market or expected to get launched in the market during the study period. The analysis covers Cancer Cachexia market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Several pharmacological and nutritional approaches have been used for the treatment of cancer cachexia. Keeping in mind that both anorexia and metabolic disturbances are involved, the development of different therapeutic strategies has focused on two major factors, namely, improving appetite and neutralizing metabolic disturbances.
The dynamics of the cancer cachexia market is anticipated to change in the coming years owing to the positive outcomes of some of the rare candidates during the developmental stage by key pharma players.
Some of the key players in the cachexia market includes:
Helsinn Healthcare
Actimed Therapeutics
Artelo Biosciences
NGM Biopharmaceuticals
And many others
The launch of emerging therapies is expected during the forecast period of 2020–2030.
Table of Content
1. Key Insights
2. Executive Summary
3. Cancer Cachexia Competitive Intelligence Analysis
4. Cancer Cachexia Market Overview at a Glance
5. Cancer Cachexia Disease Background and Overview
6. Cancer Cachexia Patient Journey
7. Cancer Cachexia Epidemiology and Patient Population
8. Cancer Cachexia Treatment Algorithm, Current Treatment, and Medical Practices
9. Cancer Cachexia Unmet Needs
10. Key Endpoints of Cancer Cachexia Treatment
11. Cancer Cachexia Marketed Products
12. Cancer Cachexia Emerging Therapies
13. Cancer Cachexia Seven Major Market Analysis
14. Attribute Analysis
15. Cancer Cachexia Market Outlook (7 major markets)
16. Cancer Cachexia Access and Reimbursement Overview
17. KOL Views on the Cancer Cachexia Market.
18. Cancer Cachexia Market Drivers
19. Cancer Cachexia Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
Related Reports
Cancer Cachexia (CC) Epidemiology Forecast 2030
DelveInsight’s ‘Cancer Cachexia (CC)– Epidemiology Forecast—2030’ report delivers an in-depth understanding of the Cancer Cachexia, historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Cancer Cachexia Pipeline Insights, 2020
Cancer Cachexia Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Cancer Cachexia market.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Anuj Rawat
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/